One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)
Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability. To support the discovery of potent and selective WRN inhibitors, WuXi AppTec offers a comprehensive platform of biophysical and biochemical assays to support hit finding and lead optimization efforts targeting WRN. Our panel of services also include high-quality WRN protein production and established X-ray crystallography protocols.
Werner Syndrome Helicase Platform
Related Content
Targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular...
VIEW RESOURCEThe Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS...
VIEW RESOURCE